Organ-On-A-Chip Technology in Drug Development

Abstract

Organ-on-a-Chip (OoC) technology is an emerging microengineering approach that combines microfluidics, living human cells, tissue engineering and biomaterials to reproduce selected structural and functional characteristics of human organs in vitro. The technology has gained attention as a human-relevant complement to conventional two-dimensional cell culture and animal models in pharmaceutical research. OoC systems can support drug discovery, disease modelling, drug screening, pharmacokinetic and pharmacodynamic studies, ADME evaluation, toxicity assessment and personalized medicine. By providing controlled fluid flow, tissue interfaces, mechanical cues and real-time monitoring, these systems can generate information that is difficult to obtain from simplified models. Patient-derived cells and induced pluripotent stem-cell-based models further create opportunities for investigating inter-individual differences in drug response. However, variability in cell sources, device design, standardization, reproducibility, scalability, cost, validation and regulatory acceptance remain important limitations. Overall, OoC technology represents a promising evidence-generating platform that may improve the human relevance, predictability and efficiency of drug development when appropriately integrated with existing pharmaceutical approaches.

Keywords: organ-on-a-chip; microfluidics; human-relevant models; drug development; ADME; toxicity; personalized medicine; pharmacology.